What is it about?
Pandoraea are uncommon bacteria that are increasingly found in people with cystic fibrosis, in immunocompromised patients and in intensive care, where they can cause lung and bloodstream infections and even outbreaks. They are naturally resistant to many antibiotics and are often misidentified by laboratories as other similar bacteria. We reviewed all available evidence on how to treat them. Most strains resist penicillins, cephalosporins, aminoglycosides, fluoroquinolones and colistin. Curiously, many remain sensitive to imipenem while being resistant to meropenem, another carbapenem, because of a specific enzyme (OXA-1152). Imipenem and trimethoprim-sulfamethoxazole are currently the most active drugs and may be combined in severe infections, while most newer antibiotics, including ceftazidime-avibactam, cefiderocol and aztreonam-avibactam, show disappointing laboratory activity.
Featured Image
Photo by Adrian Lange on Unsplash
Why is it important?
There are no official susceptibility breakpoints and no clinical trials for Pandoraea, so doctors facing these infections have little guidance. This review collects the scattered evidence into practical recommendations and highlights the knowledge gaps, helping clinicians choose therapy for an emerging multidrug-resistant pathogen in very fragile patients.
Perspectives
Rare pathogens are where clinicians feel most alone, with no guidelines to rely on. With Nicholas Geremia we wanted to provide a concise, practical tool for colleagues who suddenly find Pandoraea in a culture report. The imipenem-meropenem paradox is a beautiful example of why reading the antibiogram carefully matters.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Managing Multidrug-Resistant Pandoraea spp.: current evidence and knowledge gaps, Infezioni in Medicina, September 2025, Edizioni Internazionali srl, Divisione EDIMES Edizioni Medico-Scientifiche,
DOI: 10.53854/liim-3303-2.
You can read the full text:
Contributors
The following have contributed to this page







